Regenix for Hair Loss: What the Evidence Actually Shows

Regenix is one of the more well-known names in private hair loss treatment, and it attracts a lot of interest from people frustrated with thinning hair and uncertain about their options. The short answer is that Regenix is a personalised trichological service, not a licensed medicine, and there is currently no independent peer-reviewed clinical trial evidence to confirm it works. That does not necessarily mean it is useless, but it does mean you should go in with clear expectations and understand how it stacks up against treatments that have robust clinical backing.

What Regenix Is (and Is Not)#

Regenix describes itself as a personalised, non-pharmaceutical approach to hair loss. You attend a consultation, typically involving a visual scalp assessment or dermoscopy, and a bespoke topical formulation is prepared based on your scalp condition. These formulations usually contain botanical extracts, vitamins, and conditioning agents aimed at improving the scalp environment.

The important distinction is this: Regenix is marketed as a cosmetic and trichological service, not as a medicine. That means it is not regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and has not had to pass the same clinical trial requirements as prescription treatments. Cosmetic products and trichological services in the UK operate under different regulatory frameworks to licensed medicines, which affects both the claims they can make and the scrutiny applied to those claims.

This is not inherently sinister. Plenty of hair and scalp products exist in this space. But it does mean that any claims made about Regenix's effectiveness rest on the company's own data and anecdotal reports from clients, rather than independently verified evidence.

The Types of Hair Loss Regenix Targets#

Regenix is primarily positioned for androgenetic alopecia, the umbrella term for male and female pattern hair loss. This is the most common form of hair loss in the UK, affecting roughly half of men by age 50 and a significant proportion of women, particularly after the menopause.

Androgenetic alopecia is driven by genetic sensitivity to dihydrotestosterone (DHT), a hormone derived from testosterone. Over time, DHT causes hair follicles to shrink, producing finer, shorter hairs until the follicle eventually stops producing hair altogether.

Regenix is also sometimes sought by people experiencing:

• Telogen effluvium, which is diffuse shedding triggered by stress, illness, crash dieting, or hormonal shifts. Post-COVID hair loss falls into this category for many people.
• General scalp conditions that may be contributing to poor hair quality or thinning, such as seborrhoeic dermatitis.

For permanent follicle damage from advanced androgenetic alopecia, no topical cosmetic treatment, including Regenix, can reverse this. That applies equally to many other products in this category.

What the Evidence Says#

Regenix has not published peer-reviewed clinical trials in independent scientific journals. The company has conducted its own internal studies and reports high satisfaction rates among clients, but these have not been subjected to external peer review or placebo-controlled trial design, both of which are standard requirements in medicine.

By contrast, the two treatments most commonly recommended for androgenetic alopecia in the UK, minoxidil and finasteride, have decades of clinical trial data behind them. Minoxidil was first used for hair loss in the 1980s and has been extensively studied in both men and women. Finasteride, a DHT-blocking tablet, has strong evidence in men and is MHRA-licensed for male pattern baldness.

A 2019 review published in the Journal of the American Academy of Dermatology confirmed that minoxidil and finasteride remain the most evidence-based first-line treatments for androgenetic alopecia. Neither is a cure, but both have demonstrated statistically significant effects on slowing hair loss and, in many cases, promoting some regrowth.

Regenix sits in a different category entirely. It may offer benefits through scalp conditioning and optimising the follicular environment, but this hypothesis has not been rigorously tested.

How Regenix Compares to Minoxidil and Finasteride#

This is the comparison most people searching for Regenix are actually trying to make, so it is worth being direct about.

Minoxidil is a topical solution applied to the scalp once or twice daily. It works by widening blood vessels, improving circulation to the hair follicle, and prolonging the growth phase of the hair cycle. It is available without a prescription in most formulations and is one of the few hair loss treatments that has evidence in both men and women. Regaine, one of the most recognised minoxidil brands, is available through Totiva's hair loss service.

Finasteride is a once-daily tablet that blocks the enzyme responsible for converting testosterone to DHT. By reducing DHT levels at the scalp, it slows the miniaturisation of hair follicles. It is prescription-only in the UK and licensed for men only. Clinical trials have shown that the majority of men who take finasteride see a halt in hair loss progression, with around two-thirds experiencing some degree of regrowth over 12 to 24 months. Finasteride is available from Totiva from £14.99 for 28 tablets, following an online consultation reviewed by a UK-registered clinician.

Regenix involves regular clinic visits, personalised topical solutions, and ongoing assessments. It is a premium private service with a corresponding price tag. Treatment programmes typically cost several hundred pounds per year, often considerably more depending on the frequency of appointments and the specific formulations prescribed.

The honest summary: if your priority is evidence-based treatment with MHRA-licensed medicines that have decades of safety data, minoxidil and finasteride are the more defensible first-line options. Regenix might be considered as a complementary approach by those who value the hands-on clinical assessment and personalised scalp care, but it should not replace licensed treatments if those are appropriate for you.

Cost and What to Expect From a Regenix Programme#

Regenix clinics operate primarily in major UK cities. An initial consultation typically costs upwards of £100, with ongoing treatment programmes, including the bespoke formulations and follow-up assessments, often running to several hundred pounds annually. Prices vary by clinic location and the complexity of your treatment plan.

The programme usually involves:

1. An initial detailed scalp consultation.
2. A personalised topical formulation dispensed to you.
3. Regular follow-up appointments, typically every three to six months.
4. Ongoing adjustments to the formulation based on scalp response.

Results, if they occur, are generally reported within three to six months, though Regenix recommend committing to at least twelve months to judge effectiveness fairly. This is actually consistent with timelines for licensed treatments too: minoxidil and finasteride both require a minimum of three to six months before any meaningful assessment is possible.

When to See a GP or Dermatologist#

Some types of hair loss warrant medical investigation before spending money on any private treatment programme. You should see your GP if:

• Hair loss came on suddenly or is patchy rather than diffuse.
• You are also experiencing fatigue, weight changes, or other symptoms that might suggest an underlying condition such as hypothyroidism or iron deficiency anaemia.
• Hair loss followed a specific event such as illness, surgery, or a change in medication.
• You are a woman experiencing significant thinning, as this may warrant investigation for hormonal causes including PCOS or menopause-related changes.

Your GP can run blood tests to rule out reversible causes and, if appropriate, refer you to an NHS dermatologist. NHS dermatology waiting times can be lengthy in many parts of England, but your GP can advise on urgency and the local pathway. For androgenetic alopecia specifically, NICE does not currently have a dedicated clinical guideline, but standard clinical practice aligns with recommending minoxidil or finasteride as first-line approaches.

If you are considering a private trichology clinic, check whether the practitioner is a member of the Institute of Trichologists or the Trichological Society. These are the professional bodies for trichologists in the UK, and membership requires meeting specified training standards. Private hair clinics are not currently regulated by the Care Quality Commission (CQC) unless they also provide medical procedures, which is worth knowing before you book.

Is Regenix MHRA-Approved?#

No. Regenix is not an MHRA-licensed medicine and does not claim to be. The MHRA licenses medicines that have passed specific safety, quality, and efficacy requirements. As a cosmetic and trichological service, Regenix is not required to seek MHRA approval, and the regulatory framework it operates under is less stringent.

This is a meaningful distinction for anyone comparing it to finasteride or minoxidil. Those treatments are MHRA-licensed, meaning the regulatory body has assessed the evidence and confirmed they meet the required standards. With Regenix, that external validation does not exist.

Can You Use Regenix Alongside Prescription Treatments?#

In principle, yes. Many people who attend trichological clinics also use licensed treatments concurrently. Minoxidil and finasteride are not chemically incompatible with most topical cosmetic formulations. However, you should always inform your prescribing pharmacist or GP about any other products you are using on your scalp, as there is potential for interactions or irritation when multiple topicals are applied to the same area.

If you are considering starting finasteride or minoxidil while also attending Regenix, a good starting point is an online consultation. Totiva's pharmacist-led service lets you complete a free consultation at your own pace, and you only pay if a treatment is approved for you. You can start a hair loss consultation here.

The Bigger Picture on Hair Loss Treatment in the UK#

The UK hair loss treatment landscape has expanded considerably. Alongside minoxidil and finasteride, there is growing clinical interest in dutasteride (a more potent DHT blocker, currently used off-label for hair loss), oral minoxidil at low doses, and platelet-rich plasma (PRP) therapy. Laser therapy, specifically low-level laser therapy (LLLT), has also attracted attention, with some studies suggesting modest benefits for androgenetic alopecia, though the evidence base remains less robust than for licensed medicines.

None of these newer options have displaced minoxidil and finasteride as first-line treatments, but they represent meaningful alternatives for people who have not responded adequately or who cannot tolerate the standard treatments.

If you are in the early stages of noticing hair thinning, the most practical advice is to act sooner rather than later. Both minoxidil and finasteride are more effective at maintaining existing hair than regrowing hair that has already been lost. The longer you wait, the fewer follicles there are to rescue.

For men looking at their options, Totiva's hair loss service covers finasteride and Regaine (minoxidil), with transparent pricing and a consultation process reviewed by UK-registered clinicians. There is no subscription required, and the consultation itself is free.

Regenix may appeal to those who value the personalised scalp assessment and the attentive clinical relationship that a private trichology programme offers. But if you are weighing it against licensed treatments on evidence alone, the gap is substantial. Starting with what works, and what is regulated, is the sensible first step.